Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Intangibles (2016 - 2022)

Ovid Therapeutics filings provide 7 years of Intangibles readings, the most recent being $244000.0 for Q1 2022.

  • Quarterly Intangibles fell 7.22% to $244000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $244000.0 through Mar 2022, down 7.22% year-over-year, with the annual reading at $263000.0 for FY2021, 17.55% down from the prior year.
  • Intangibles hit $244000.0 in Q1 2022 for Ovid Therapeutics, down from $263000.0 in the prior quarter.
  • Across five years, Intangibles topped out at $467000.0 in Q4 2019 and bottomed at $160390.0 in Q1 2018.
  • Average Intangibles over 5 years is $316341.2, with a median of $319000.0 recorded in 2020.
  • The largest annual shift saw Intangibles skyrocketed 234.71% in 2018 before it plummeted 45.43% in 2021.
  • Ovid Therapeutics' Intangibles stood at $392000.0 in 2018, then rose by 19.13% to $467000.0 in 2019, then plummeted by 31.69% to $319000.0 in 2020, then fell by 17.55% to $263000.0 in 2021, then fell by 7.22% to $244000.0 in 2022.
  • Per Business Quant, the three most recent readings for OVID's Intangibles are $244000.0 (Q1 2022), $263000.0 (Q4 2021), and $197000.0 (Q3 2021).